Our History | Clinigen

Clinigen was formed through the merger of three successful companies: Keats Healthcare, Clinigen Healthcare and Clinigen.

2010

Clinigen acquires its first product, Foscavir and commences Global Access Programs supplying unlicensed medicines globally
Employees: 32

Clinigen recognised as the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100
Employees: 48

Clinigen moves warehousing into brand new Operations Centre
Clinigen lists on the Alternative Investment Market (AIM) of the London Stock Exchange – the first UK healthcare company to list in London in five years
Employees: 72

Clinigen marks its first year as a public company by winning Best Newcomer at the London Stock Exchange AIM Awards
Clinigen wins IPO of the Year at the 2013 M&A Awards
Clinigen SP acquires its second product, Cardioxane
Employees: 101

Clinigen opens new, extended headquarters in Burton-on-Trent, UK
Clinigen acquires its third product, Savene
Clinigen acquires its fourth product, Ethyol
Clinigen launches its new web portal, Cliniport, which allows healthcare professionals to order products directly via the internet
Employees: 116

Clinigen acquires Idis in April 2015 to become the global leader in providing ethical compliant access to unlicensed medicines
Clinigen acquires Link Healthcare in October 2015 to expand its ability to provide access to medicines for patients in the Africa, Asia and Australia regions
Clinigen awarded the ServiceMark accreditation by The Institute of Customer Service, in recognition of the Group’s commitment to, and achievement in, customer services
Employees: 450

Launch of Japanese business, Clinigen KK, with Foscavir as its first product
Clinigen acquires its fifth product, Totect US, completing the global dexrazoxane portfolio
Clinigen continues Foscavir development with purchase of a new bag presentation
Clinigen launches Ethyol in the US in partnership with Cumberland Pharma
Employees: 530

Clinigen receives investors in people silver award
Clinigen receives EC approval for updates to Cardioxane product information
Clinigen launched Totect in the US in partnership with Cumberland Pharma
Clinigen acquires IMMC, Japan’s largest supplier of unlicensed medicines
Clinigen acquires Quantum Pharma plc in November 2017 extending its Unlicensed Medicines capability and accelerating its unlicensed to licensed global strategy
Employees: 849

Clinigen signs extended partnership agreement with Bristol-Myers Squibb to supply its portfolio of products in South Africa
Clinigen acquires its sixth product, Proleukin (global rights outside the US)
Clinigen acquires its seventh product, Imukin (global rights outside the US, Canada and Japan)
Clinigen acquires CSM a specialist provider of packaging, labelling, warehousing and distribution services with infrastructure in the US, Belgium and Germany
Clinigen acquires iQone, a Swiss-based specialty pharmaceutical business providing EU medical scientific liaison (MSL) capability
Employees: 1,182

Clinigen acquires the US rights to Proleukin
Clinigen Direct is a globally available service which helps clinicians, pharmacists and pharmacy technicians source hard to find medicines by connecting them with our specialist customer services team, either online or by phone (and even fax).

Clinigen signs exclusive global licensing and distribution agreement to commercialise Erwinase
Clinigen and GC Pharma collaboratively submit New Drug Application for Hunterase (Idursulfase-beta) ICV in Japan
Clinigen expands footprint in Southeast Asia with opening of new Malaysia office

Launched Hunterase in Japan and begin roll-out of Erwinase in licenced and unlicenced markets. COVID-19 headwinds impact demand for Proleukin and On-Demand. Divestment of UK Specials and Aseptics business
As announced in the half year results, from 1 January 2021, the Group structure was simplified, moving from three divisions to two: Services and Products. This change better reflects the alignment of the Group’s activities to its end customers: pharmaceutical clients and healthcare professionals